BACKGROUND: Cytokeratin immunohistochemistry (IHC) reveals a higher rate of occult lymph node metastases among lobular carcinomas than among ductal breast cancers. IHC is widely used but is seldom recommended for the evaluation of sentinel lymph nodes in breast cancer patients. OBJECTIVE: To assess the value of cytokeratin IHC for the detection of metastases in sentinel lymph nodes of patients with invasive lobular carcinoma. METHODS: The value of IHC, the types of metastasis found by this method, and the involvement of non-sentinel lymph nodes were analysed in a multi-institutional cohort of 449 patients with lobular breast carcinoma, staged by sentinel lymph node biopsy and routine assessment of the sentinel lymph nodes by IHC when multilevel haematoxylin and eosin staining revealed no metastasis. RESULTS: 189 patients (42%) had some type of sentinel node involvement, the frequency of this increasing with increasing tumour size. IHC was needed for identification of 65 of these cases: 17 of 19 isolated tumour cells, 40 of 64 micrometastases, and 8 of 106 larger metastases were detected by this means. Non-sentinel-node involvement was noted in 66 of 161 cases undergoing axillary dissection. Although isolated tumour cells were not associated with further lymph node involvement, sentinel node positivity detected by IHC was associated with further nodal metastases in 12 of 50 cases (0.24), a proportion that is higher than previously reported for breast cancer in general. CONCLUSIONS: IHC is recommended for the evaluation of sentinel nodes from patients with lobular breast carcinoma, as the micrometastases or larger metastases demonstrated by this method are often associated with a further metastatic nodal load.
BACKGROUND: Cytokeratin immunohistochemistry (IHC) reveals a higher rate of occult lymph node metastases among lobular carcinomas than among ductal breast cancers. IHC is widely used but is seldom recommended for the evaluation of sentinel lymph nodes in breast cancerpatients. OBJECTIVE: To assess the value of cytokeratin IHC for the detection of metastases in sentinel lymph nodes of patients with invasive lobular carcinoma. METHODS: The value of IHC, the types of metastasis found by this method, and the involvement of non-sentinel lymph nodes were analysed in a multi-institutional cohort of 449 patients with lobular breast carcinoma, staged by sentinel lymph node biopsy and routine assessment of the sentinel lymph nodes by IHC when multilevel haematoxylin and eosin staining revealed no metastasis. RESULTS: 189 patients (42%) had some type of sentinel node involvement, the frequency of this increasing with increasing tumour size. IHC was needed for identification of 65 of these cases: 17 of 19 isolated tumour cells, 40 of 64 micrometastases, and 8 of 106 larger metastases were detected by this means. Non-sentinel-node involvement was noted in 66 of 161 cases undergoing axillary dissection. Although isolated tumour cells were not associated with further lymph node involvement, sentinel node positivity detected by IHC was associated with further nodal metastases in 12 of 50 cases (0.24), a proportion that is higher than previously reported for breast cancer in general. CONCLUSIONS: IHC is recommended for the evaluation of sentinel nodes from patients with lobular breast carcinoma, as the micrometastases or larger metastases demonstrated by this method are often associated with a further metastatic nodal load.
Authors: Thorsten Kuehn; Andreas Bembenek; Thomas Decker; Dieter Ludwig Munz; Marie-Luise Sautter-Bihl; Michael Untch; Diethelm Wallwiener Journal: Cancer Date: 2005-02-01 Impact factor: 6.860
Authors: M Hubalek; R Bartsch; M Gnant; K S Kapp; A Lang; S Lax; P Lukas; W Neunteufel; G Pristauz; R Reitsamer; P Sandbichler; P Schrenk; C Singer; K Tamussino; J Tschmelitsch; A G Zeimet; C Marth Journal: Geburtshilfe Frauenheilkd Date: 2012-04 Impact factor: 2.915
Authors: Gábor Cserni; Simonetta Bianchi; Vania Vezzosi; Riccardo Arisio; Rita Bori; Johannes L Peterse; Anna Sapino; Isabella Castellano; Maria Drijkoningen; Janina Kulka; Vincenzo Eusebi; Maria P Foschini; Jean-Pierre Bellocq; Cristi Marin; Sten Thorstenson; Isabel Amendoeira; Angelika Reiner-Concin; Thomas Decker; Manuela Lacerda; Paulo Figueiredo; Gábor Fejes Journal: Pathol Oncol Res Date: 2007-03-27 Impact factor: 3.201
Authors: Elizabeth A Mittendorf; Aysegul A Sahin; Susan L Tucker; Funda Meric-Bernstam; Min Yi; Khazi M Nayeemuddin; Gildy V Babiera; Merrick I Ross; Barry W Feig; Henry M Kuerer; Kelly K Hunt Journal: Ann Surg Oncol Date: 2008-09-25 Impact factor: 5.344
Authors: Carolien H M van Deurzen; Maaike de Boer; Evelyn M Monninkhof; Peter Bult; Elsken van der Wall; Vivianne C G Tjan-Heijnen; Paul J van Diest Journal: J Natl Cancer Inst Date: 2008-11-11 Impact factor: 13.506
Authors: Miguel Alonso Ruano; Eugeni Lopez-Bonet; Maria Buxó; Francesc Tuca-Rodríguez; Ester Vila-Camps; Elena Alvarez; Begoña Martin-Castillo; Javier A Menendez Journal: Sci Rep Date: 2014-07-18 Impact factor: 4.379